Zoladex withdrawal may leave women without vital treatment

AstraZeneca is withdrawing Zoladex, a crucial drug for breast cancer and endometriosis, from the Pharmaceutical Benefits Scheme and private market in November. Experts warn that this decision may leave thousands of women without access to the treatment, although some existing patients can access it for an additional six months.

Read the full story at The Guardian AU→